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The hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
are secreted postprandially from intestinal K- and L-cells, respectively. As incretins, these hormones
stimulate insulin secretion from the pancreatic b-cell, and have independently been implicated in the
control of food intake and lipid metabolism. Whilst the enteroendocrine cells producing GIP and GLP-1
are therefore attractive targets for the treatment of diabetes and obesity, our understanding of their
physiology is fairly limited. The mechanisms employed to sense the arrival of carbohydrate, fat and
protein in the gut lumen have been investigated using organ perfusion techniques, primary epithelial
cultures and cell line models. The recent development of mice with ﬂuorescently labeled GIP or GLP-1-
expressing cells is now enabling the use of single cell techniques to investigate stimulus-secretion
coupling mechanisms. This review will focus on the current knowledge of the molecular machinery
underlying nutrient sensing within K- and L-cells.
 2009 Elsevier Ltd. Open access under CC BY license.Contents
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The term ‘‘incretin effect’’ describes the observation that orally
ingested glucose stimulates insulin secretion more potently than
intravenously administered glucose, even when plasma glucose
excursions are matched (Creutzfeldt, 1979; Elrick, Stimmler, Hlad, &
Araim, 1964). The effect originates from two hormones, glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1), which are secreted from enteroendocrine cells
embedded in the gut epithelium. These so-called ‘‘incretins’’ are
believed to act directly on the pancreatic b-cell, which expresses
speciﬁc G-protein coupled receptors (GPRs) for both theseY license.hormones (Baggio & Drucker, 2007). Receptor stimulation increases
cytosolic concentrations of cyclic adenosine monophosphate
(cAMP), which in turn boosts insulin secretion, albeit only under
permissive conditionswhen secretion is simultaneously initiated by
elevated blood glucose levels (Gromada, Holst, & Rorsman, 1998).
The resulting relatively small risk of inducing hypoglycaemia, and
the observation that some of the recently introduced incretin based
medications for type-2 diabetes are associatedwith weight loss, are
major advantages over older insulinotropicmedications, such as the
sulphonylureas. Current drugs that exploit the GLP-1 axis are based
either on GLP-1 mimetics or on inhibition of dipeptidylpeptidase IV
(DPP-IV), which normally rapidly inactivates incretin hormones,
limiting their plasma half lives to 2–5 min (Brubaker, 2007). Both
these approaches have drawbacks, as mimetics need to be injected
due to their peptidergic nature, while DPP-IV inhibition affects the
processing of many other peptides, and for example interferes with
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suppresses appetite in its active form (Ballantyne, 2006). Alternative
approaches, such as the stimulation of intestinal L-cells, which
secrete both GLP-1 and PYY, seem feasible, but would beneﬁt from
a greater understanding of the physiology of enteroendocrine cells.
Although GIP is believed to contribute at least as much as GLP-1
to the incretin effect under normal physiological conditions, the
situation is complicated by the different insulinotropic efﬁciencies
of GIP and GLP-1 in the context of diabetes. Thus, whilst pharma-
cological levels of GLP-1 or its DPP-IV resistant analogues undis-
putedly promote insulin secretion in type-2 diabetic patients,
raising GIP levels is widely reported to be ineffective (Holst, 2007;
Nauck et al., 1993). In a recent publication, GIP-receptor agonists
were found still to increase insulin levels in subjects with newly
diagnosed type-2 diabetes, but postprandial glucose excursions
were not improved, possibly due to a simultaneous glucagono-
tropic effect (Chia et al., 2009). This is in marked contrast to the
action of GLP-1-receptor agonists, which inhibit, rather than
promote, glucagon secretion from the pancreatic a-cell (Vilsbøll,
Krarup, Madsbad, & Holst, 2003). In addition there is increasing
evidence that activation of the GIP-receptor has other undesirable
effects, possibly acting in extrapancreatic locations such as adipo-
cytes, where it promotes lipid storage (Kim, Nian, & McIntosh,
2007; Yip, Boylan, Kieffer, & Wolfe, 1998). Mice in which GIP-action
is prevented by knocking out the GIP-receptor (Miyawaki et al.,
2002), by treatment with a GIP-receptor antagonist (Gault
et al., 2005, 2007) or by ablation of GIP-secreting cells (Althage
et al., 2008), are somewhat protected from developing obesity on
a high-fat diet or on the leptin-deﬁcient, hence overeating, ob/ob-
background. The leaner mice resulting from impaired GIP-signal-
ling have better glucose tolerance than their fat littermates when
assessed by an oral glucose tolerance test. As interference with GIP-
action in non-obese mice worsens their glucose homeostasis (Gault
et al., 2003; Miyawaki et al., 1999; Tseng, Kieffer, Jarboe, Usdin, &
Wolfe, 1996), this might reﬂect the observation that GIPs incretin
action seems to be impaired under chronic hyperglycaemic
conditions, possibly due to fast downregulation of the GIP-receptor
on pancreatic b-cells (Xu et al., 2007, Zhou et al., 2007). However, if
the results from the rodent studies transfer to humans, it appears
one would wish to stimulate GLP-1 secretion from L-cells, while
simultaneously not affecting, or rather inhibiting, GIP secretion
fromK-cells. This might not easily be achievable as some cells in the
proximal small intestine have been reported to contain both GLP-1
and GIP (Mortensen, Christensen, Holst, & Orskov, 2003), withw1/
3 of all cells examined showing staining for both peptides (Theo-
dorakis et al., 2006).
Until recently, very little was known about the molecular
mechanisms underlying stimulus-secretion coupling in either K- or
L-cells. Some conclusions about the nutrient sensing machinery
could be drawn from studies in which incretin hormone release
was measured in the whole body or upon luminal or vascular
perfusion of isolated intestine (for review see Deacon, 2005). The
drawback of these experiments is the uncertainty of whether the
identiﬁed mechanisms are located within the incretin-secreting
cells themselves or if they depend on communications with other
cells, such as the surrounding enterocytes, neurons or paracrine
inﬂuences from other enteroendocrine cells. Intracellular pathways
in L- and K-cells have been postulated from the use of murine cell
lines, such as the colonically derived GLUTag cell and the small
intestinally derived STC-1 cell. Studies on primary cells have been
limited by the inability to distinguish or isolate living enter-
oendocrine cells from the surrounding enterocytes. In this review I
shall discuss recent insights into the sensing mechanisms for
carbohydrate, lipids and protein characterised in incretin-secreting
cell lines and more recently in primary K- and L-cells identiﬁablethrough the transgenic expression of the ﬂuorescent protein Venus
under the control of the GIP- and proglucagon-promoter,
respectively.
GIP-secreting K-cells are found in the proximal small intestine,
particularly the duodenum (Buchan, Polak, Capella, Solcia, & Pearse,
1979; Polak, Bloom, Kuzio, Brown, & Pearse, 1973), and are hence
ideally placed to sense nutrient arrival in the gut. K-cell
morphology, described as being ‘‘open-type’’ because of the
microvillus-rich apical membrane directly facing the gut lumen,
suggests that they might sense luminal contents directly. The mere
presence of macronutrients in the gut lumen, however, is not
sufﬁcient to trigger GIP release, as pathophysiological (Besterman
et al., 1978, 1979; Ebert & Creutzfeldt, 1980; Ebert, Creutzfeldt,
Brown, Frerichs, & Arnold, 1976) or pharmacological (Fushiki,
Kojima, Imoto, Inoue, & Sugimoto, 1992) inhibition of sugar
absorption reduces GIP release in vivo.
The density of GLP-1 secreting L-cells, by contrast, increases
along the length of the intestine, with the highest densities found
in the colon and rectum, and only relatively low numbers located in
the proximal small intestine (Eissele et al., 1992). It has hence been
suggested that GLP-1 secretion in response to oral glucose does not
involve direct sensing by L-cells, but rather reﬂects activation of
upstream sensors which stimulate the distally located L-cells either
by intestinal hormonal and/or neuronal loops (Rocca & Brubaker,
1999). However, L-cells are also open-type cells (Eissele et al., 1992),
and L-cell model lines, like GLUTag, have been shown to respond to
a number of nutrients, including glucose (Reimann & Gribble,
2002).
2. Carbohydrate sensing
As GIP-secreting cells were found to express glucokinase
(hexokinase-IV), which has a restricted expression proﬁle (Cheung
et al., 2000; Jetton et al., 1994), it was hypothesised that glucose-
sensing in K-cells must involve a mechanism similar to that
employed by the pancreatic b-cell, where this enzyme plays a key
role. Insulin secretion from b-cells is triggered in response to ﬂux
increases in glucose metabolism. B-cells express sufﬁcient facilita-
tive glucose transport capacity (GLUT-2) to allow rapid equilibra-
tion of the surrounding glucose concentration with that in the
cytosol. Glucokinase, with its half maximal activity at w8 mM
glucose, is well suited to monitor physiological changes in ambient
glucose concentration, in contrast to the ubiquitously expressed
hexokinases I–III, which become saturated at glucose concentra-
tions in the range ofw2–5 mM (Matschinsky, 2002). The resulting
increased ﬂux through glycolysis and the mitochondrial citric acid
cycle results in a rise in the cytosolic ATP/ADP ratio. This in turn
closes ATP-sensitive potassium channels (KATP), leading to a net
depolarization of the plasma membrane potential, which activates
voltage gated Ca2þ-channels. The consequent rise in cytosolic Ca2þ
triggers vesicular fusion with the plasma membrane and release of
stored insulin into the surroundings.
A single report investigated GIP secretion from canine epithelial
cells in primary culture after partial enrichment for K-cells
(tow10%) by elutriation (Kieffer, Buchan, Barker, Brown, & Pederson,
1994). In addition to glucose, elevation of the extracellular Kþ-ion
concentration was found to be a potent secretory stimulus, thus
establishing plasma membrane depolarization as a trigger for GIP
release. However, direct glucose-sensing by K-cells has been
disputed, as an STC-1 derived cell line did not increase its rate of
secretion in response to either glibenclamide or glucose (Ramshur,
Rull, & Wice, 2002), although other STC-1 derived cell lines have
been shown to respond to glucose (Cheung et al., 2000; Kieffer et
al., 1995). The lack of a sulphonylurea response reported by Ram-
shur et al. corresponded with other work by the same group failing
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murine intestinal slices by immunohistochemistry (Wang, Chi, Li,
Moley, & Wice, 2003). Nevertheless, expression of KATP-channel
subunits has since been demonstrated in GIP- and GLP-1-express-
ing cells in the human intestine (Nielsen et al., 2007), and the KATP-
channel opener diazoxide has been shown to decrease glucose-
stimulated GIP release in dogs (Williams, 1979). Recently, expres-
sion of key glucose-sensing genes has been investigated in K-cells
isolated by ﬂuorescent assisted cell sorting (FACS) from transgenic
mice expressing the ﬂuorescent protein Venus under the control of
the GIP-promoter (Parker, Habib, Rogers, Gribble, & Reimann,
2009). mRNAs for glucokinase and the KATP-channel subunits Kir6.2
and SUR1 were found at levels comparable with those found in the
pancreatic b-cell by quantitative PCR. Moreover, tolbutamide,
a suphonylurea that closes KATP-channels, triggered GIP release
from mixed epithelial cultures isolated from mouse duodenum.
However, while glucose responses in these cultures improved
when cAMP-levels were pharmacologically raised, the cells became
unresponsive to tolbutamide, suggesting that KATP-channels are
closed in K-cells at elevated cAMP concentrations and do not
participate in glucose-sensing under these conditions.
Initial studies with canine L-cells in primary culture, isolated by
elutriation, failed to detect glucose induced GLP-1 secretion
(Damholt, Buchan, & Kofod, 1998). However, studies on the murine
GLUTag cell line, which expresses GLP-1, but not GIP, have
demonstrated responses to both glucose and tolbutamide (Reim-
ann & Gribble, 2002). In contrast to the ﬁndings with K-cells in
primary culture, tolbutamide stimulated GLP-1 release from GLU-
Tag cells in the presence as well as the absence of raised cAMP-
levels. RT-PCR detected the presence of glucokinase, Kir6.2 andFig. 1. Glucose triggered electrical activity in L-cells. a) Venus-labeled L-cells in an ileal tis
transgenic for the yellow ﬂuorescent protein Venus under the control of the proglucagon-pro
colonic epithelial culture. (left) phase contrast, scale bar 20 mm (right) ﬂuorescence image o
positive cell in colonic epithelial culture. The cell was in perforated whole-cell current clam
potential ﬁring rate from w0.3 to w1.1 Hz (see Reimann et al., 2008 for methodological deSUR1 in GLUTag cells, and an increase in the ambient glucose
concentration was shown to increase intracellular ATP-levels
(Reimann, Williams, da Silva Xavier, Rutter, & Gribble, 2004).
Studies with colonic L-cells, identiﬁed by the transgenic expression
of the ﬂuorescent protein Venus under the control of the proglu-
cagon-promoter, conﬁrmedmany of the cell line ﬁndings (Reimann
et al., 2008; Fig. 1). Primary L-cells were electrically active and
increased their action potential frequency in response to either
glucose or tolbutamide. This corresponded to an increase in cyto-
solic Ca2þ, as monitored by Fura-2 ﬂuorescence changes, and
enhanced GLP-1 release in mixed epithelial cultures in response to
either treatment, suggesting that glucose metabolism and subse-
quent KATP-closure can trigger GLP-1 secretion (Fig. 2).
Despite the clear presence of KATP-channels in human and
mouse K and L cells, it seems that KATP-channel closure does not,
itself, act as the key link between elevated luminal glucose levels
and incretin secretion. Mice lacking KATP-channels, for example,
were found to exhibit elevated, rather than suppressed, peak GIP
levels after glucose ingestion, when compared with wild type
controls (Miki et al., 2005). Furthermore, studies in humans have so
far failed to detect signiﬁcant changes in plasma GIP or GLP-1 in
response to sulphonylureas (El-Ouaghlidi et al., 2007). To further
address the role of the KATP-channel in K- or L-cells it might be
interesting to look at the incretin responses of patients with inac-
tivating mutations in the KATP-channel. These patients usually
suffer from severe hypoglycaemia shortly after birth due to inap-
propriate hypersecretion of insulin from the pancreatic b-cell and
consequently have often undergone lifesaving resection of the
pancreas or are sometimes treated with diazoxide, a KATP-channel
opener. However, patients with KATP-channel mutations, whichsue slice. Phase contrast image of intestinal cells in an ileal slice taken from a mouse
moter. Venus-ﬂuorescence was excited at 480 nm. b) Venus positive cells in a 7 day old
verlay, with Venus (green) and DAPI (blue). c) Current clamp recording from a Venus
p. Application of 10 mM glucose, as indicated by the bar, resulted in an increased action
tails).
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Fig. 2. Nutrient sensing machinery in K- and L-cells. As in other endocrine cells,
secretion is triggered by an elevation in cytosolic Ca2þ, which promotes fusion of
hormone containing vesicles with the plasma membrane. This can be achieved in
different ways: (i) Uptake: (left) Electroneutral uptake of nutrients increases metabolic
ﬂux and elevates cytosolic ATP-levels. These close ATP-sensitive potassium channels
(KATP), permitting depolarization of the plasma membrane and opening of voltage
gated sodium and calcium channels (Reimann et al., 2008), leading to an elevation in
cytosolic Ca2þ. (right) Electrogenic transport of nutrients directly depolarizes the
plasma membrane and triggers all the subsequent steps. (ii) Alternatively nutrients
might trigger hormone release without ever entering the cell by interaction with
surface sensors. Examples for this type of detection involve activation of ligand gated
ion channels (hence electrogenic (left) and feeding into the same triggering pathway as
the depolarizing transport mechanisms) or (right) electroneutral activation of second
messenger cascades. Examples of transporters/receptors identiﬁed in incretin-
secreting cells are given for each of these mechanisms, with the colours corresponding
to the macronutrients detected (see text for details).
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have neonatal diabetes, due to defective insulin secretion from the
pancreatic b-cell, but do not seem to have altered secretion of GLP-1
(Pearson et al., 2006). Similarly, patients with mutations in gluco-
kinase, who suffer from maturity onset of diabetes in the young
(MODY-2), appear to have normal incretin secretion (Murphy et al.,
2009), suggesting that while the molecular machinery employed
for glucose-sensing by the pancreatic b-cell is present, it does not
seem to play as dominant a role in the stimulus-secretion coupling
of either K- or L-cells.
An involvement of sodium-dependent glucose uptake in trig-
gering incretin secretion has been suggested on the basis of the
monosaccharide structure potency relationship in rodents and the
sensitivity of glucose-stimulated GIP secretion to phloridizin
(Ritzel, Fromme, Ottleben, Leonhardt, & Ramadori, 1997; Sykes,
Morgan, English, & Marks, 1980). Sodium-coupled glucose trans-
porter-1 (SGLT-1) has been shown to be expressed in the apical
membrane of K-cells, and murine duodenal cultures secreted GIP
in response to 10 mM a-methyl-glucopyranoside (a-MDG), a non-
metabolisable glucose analogue transported by SGLT-1 (Parker
et al., 2009). While the response to a-MDG was sensitive to
phloridizin, as expected, it was also abolished by diazoxide, a KATP-
channel opener, suggesting that the mechanism involves depo-
larization of the plasma membrane, due to the coupled inﬂow of
positively charged sodium ions. Consistent with this idea, a-MDG
responses were only observed in the presence of raised cAMP-
levels, when KATP-channels appeared to be predominantly closed
in these cells. In the GLUTag cell line, high concentrations of a-
MDG (100 mM) increased action potential ﬁring, and glucose-
triggered electrical activity was inhibited in the additionalpresence of phloridizin (Gribble, Williams, Simpson, & Reimann,
2003). a-MDG (100 mM) triggered an inward current of w5 pA/
cell, consistent with the typical magnitude of transporter currents,
which was absent when extracellular Naþ was omitted. Smaller,
but signiﬁcant inward currents were recorded in response to
20 mM glucose. Expression of both SGLT-1 and SGLT-3a was
detected by reverse transcription polymerase chain reaction (RT-
PCR). It was subsequently reported that human, but not rabbit
SGLT-3, lacks glucose transport capacity, and rather acts as
a glucose gated ion channel (Diez-Sampedro et al., 2003). While
this raises the interesting possibility that SGLT-3 acts a speciﬁc
surface sensor for glucose, the fact that 3-O-methyl-glucose (3-
OMG), which is a substrate for SGLT1 but not SGLT-3 (Dı´ez-Sam-
pedro, Lostao, Wright, & Hirayama, 2000; Voss, Dı´ez-Sampedro,
Hirayama, Loo, & Wright, 2007), triggers GLP-1 secretion (Reimann
and Gribble, unpublished) suggests that the SGLT-3 transporter/
sensor cannot, on its own, account for the observed incretin
secretory responses to ingested sugars. Interestingly, primary
epithelial cultures from murine small or large intestine secreted
GLP-1 in response to 10 mM a-MDG even without pharmacological
elevation of cytosolic cAMP-levels. As similar cultures secreted
GLP-1 in response to tolbutamide, it seems that L-cells and K-cells
may differ in their balance between the depolarizing SGLT-
mechanism and counteracting resting KATP conductance. A recent
publication investigated the effects of non-metabolisable glucose
analogues on glucose homeostasis in mice in vivo (Moriya, Shir-
akura, Ito, Mashiko, & Seo, 2009). Not only was incretin secretion
triggered by a-MDG and 3-OMG, but subchronic treatment of mice
with 3% a-MDG in the drinking water for 13 days reduced the
plasma glucose excursions in obese db/db mice in response to an
oral glucose tolerance test. As this was observed without signiﬁ-
cant differences in body fat or weight, it suggests that chronic
activation of sodium-coupled glucose transport might be
a strategy to increase incretin secretion in the treatment of dia-
betes. An alternative explanation, however, could simply be
a chronic reduction in the absorptive capacity of the small intes-
tine and this needs to be further investigated. Further insight into
the role of SGLT-1 in incretin secretion in humans might also be
gained by studying patients harbouring mutations in the human
SGLT-1 gene. These mutations, which either interfere with SGLT-1
transport capacity or its targeting to the brush border membrane,
result in glucose/galactose malabsorption with severe diarrhoea,
and are treated by exclusion of these sugars from the diet (Wright,
Hirayama, & Loo, 2007). Incretin responses in patients lacking
functional SGLT-1 have not, to my knowledge, been reported to
date.
A third glucose-sensing mechanism identiﬁed in incretin-
secreting cells involves G-protein coupled taste receptors. Taste
receptor family 1 members 2 and 3 (Tas1R2 and Tas1R3) form
relatively glucose sensitive heterodimers, which are found in sweet
sensing papillae cells of the tongue (Chandrashekar, Hoon, Ryba, &
Zuker, 2006). Expression of these receptors and the coupled G-
protein gustducin have been reported in incretin-secreting cells
(Dyer, Salmon, Zibrik, & Shirazi-Beechey, 2005; Rozengurt et al.,
2006), and secretory responses to artiﬁcial sweeteners were
demonstrated for example in the GLUTag and NCI-H716 cell lines,
while gustducin knock-out animals showed impaired GLP-1
secretion (Jang et al., 2007; Margolskee et al., 2007). However,
studies on primary murine L- and K-cells could barely detect Tas1R
expression by quantitative PCR, and 1 mM sucralose, a saturating
dose of this artiﬁcial sweetener on Tas1R2/3, did not signiﬁcantly
stimulate GIP or GLP-1 secretion from mixed intestinal epithelial
cultures (Parker et al., 2009; Reimann et al., 2008). Subsequent in
vivo studies could not detect signiﬁcant increases in plasma incretin
levels in response to artiﬁcial sweetener ingestion in rodents (Fujita
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although one study reported a signiﬁcantly greater GLP-1 response
to an oral glucose load, when diet-soda rather than carbonated
water was consumed 30 min before the glucose stimulus (Brown,
Walter, & Rother, 2009). However, as intestinal cells expressing
Trpm5, a channel indispensable for taste perception through Tas1R
signaling (Zhang et al., 2003), have now been reported not to
express GLP-1 (Kokrashvili et al., 2009), the role of this pathway in
glucose-triggered incretin secretion is far from clear.
3. Lipids
Due to their role in glucose homeostasis, much research has
focused on the carbohydrate sensing of K- and L-cells. Whilst
glucose ingestion results in a relatively rapid elevation of plasma
GIP levels, fat ingestion triggers a greater and longer lasting GIP-
response when compared on a molar basis (Falko, Crockett,
Cataland, & Mazzaferri, 1975; Krarup, Holst, & Larsen, 1985). The
molecular mechanisms underlying fat-stimulated GIP secretion,
which under these somewhat artiﬁcial nutritional circumstances
clearly does not function as an incretin, are only beginning to be
understood and seem also be present in GLP-1 secreting L-cells. It
has been reported that ingested triglycerides need to be hydro-
lysed to long-chain free fatty acids to stimulate GIP- or GLP-1
secretion (Ellrichmann et al., 2008; Enç et al., 2009; Kwasowski,
Flatt, Bailey, & Marks, 1985; Pilichiewicz et al., 2003; Ross &
Shaffer, 1981), and oils rich in monounsaturated fatty acid seem to
be more potent than fats rich in saturated fatty acids (Lardonois,
Starich, & Mazzaferri, 1988; Thomsen et al., 1999). One mechanism
compatible with these observations has been described in the
GLUTag cell line and involves activation of the atypical protein
kinase C zeta (Iakoubov, Izzo, Yeung, Whiteside, & Brubaker, 2007).
Long-chain unsaturated fatty acids are also ligands for the Gq-
protein coupled ‘‘free fatty acid receptors’’ GPR40 (Briscoe et al.,
2003; Itoh et al., 2003) and GPR120 (Hirasawa et al., 2005). mRNAs
for both these receptors are detected by quantitative PCR in L- and
K-cells (Parker et al., 2009; Reimann et al., 2008), as well as in
pancreatic a- and b-cells (unpublished). Knock-down of GPR120,
but not GPR40, interfered with CCK-release from STC-1 cells
(Tanaka et al., 2008) and selective GPR120 agonists, but not
selective GPR40-agonists, triggered secretion of GLP-1 from this
cell line (Hara et al., 2009). Short chain fatty acids, products of
bacterial fermentation in the colon, have been shown to stimulate
the related G-protein coupled receptors GPR41 and GPR43, which
have been localized immunohistochemically on L-cells in rat and
human (Karaki et al., 2006; Tazoe et al., 2008). Other compounds
elevated in the gut lumen after a lipid rich meal, such as lyso-
phosphatidylcholine, oleoylethanolamide or bile acids, have been
shown to stimulate the Gs-protein coupled receptors GPR119 and
TGR5, respectively. GPR119 agonists stimulate GIP and GLP-1
secretion in vivo (Chu et al., 2008; Lauffer et al., 2009), while TGR5
activation has been shown to stimulate GLP-1 secretion from STC-
1 cells. Both GPR119 and TGR5 knock-out animals showed atten-
uated postprandial GLP-1 secretion, but did not exhibit signiﬁ-
cantly altered glucose homeostasis, even when challenged with
a high-fat diet (Chu et al., 2008; Lan et al. 2009; Thomas et al.,
2009). Similarly, GPR40 knock-out animals showed signiﬁcantly
reduced plasma GIP and GLP-1 levels on a high-fat diet, yet
GPR40/ mice are not signiﬁcantly protected from developing
diet induced obesity, and different laboratories have reported
inconsistent effects on glucose homeostasis in high-fat fed mice
(Edfalk, Steneberg, & Edlund, 2008; Kebede et al., 2008; Lan et al.,
2008; Steneberg, Rubins, Bartoov-Shifman, Walker, & Edlund,
2005). Obviously, effects on glucose homeostasis are complicated
because of the expression of all the above-mentioned GPRs onboth gut enteroendocrine and pancreatic islet cells and cross talk
between these cells, as for example insulin has itself been reported
to stimulate GLP-1 secretion (Lim et al., 2009). Further problems
arise from possible ‘‘lipotoxic’’ effects due to chronic activation of
these receptors, which might counteract their acute stimulatory
effects on hormone secretion (Alquier & Poitout, 2009; Steneberg
et al., 2005). The recent availability of more selective pharmaco-
logical tools, possibly in combination with conditional knock-out
technology, should clarify the importance of these GPRs for lipid
stimulated incretin secretion, and enable an assessment of the
relative contribution of the incretin effect to the global metabolic
outcome of targeting these receptors therapeutically.
4. Protein
Protein is usually considered the least effective of the macro-
nutrients at stimulating incretin secretion. However, intraluminal
administration of amino acids (Thomas et al., 1976, 1978) or acidi-
ﬁcation (LeRoith et al., 1980) have been shown to stimulate GIP
release. Furthermore, meat hydrolysate is reported to be one of the
strongest stimuli of GLP-1 secretion from the human NCI-H716 cell
line (Reimer et al., 2001) and also stimulates GIP and GLP-1
secretion from STC-1 and GLUTag cells (Cordier-Bussat et al., 1998).
The mechanism for this is unclear, but secretion can be inhibited by
drugs targeting voltage gated Ca2þ-channels and hence presumably
involves plasma membrane depolarization (Ramshur et al., 2002),
which could be achieved by electrogenic co-transport of small
peptides and protons by the PepT1 transporter. However, in the
STC-1 cell line this could only be demonstrated after expression
levels of PepT1 were boosted by transfection (Matsumura, Miki,
Jhomori, Gonoi, & Seino, 2005) and alternatively an activation of
mitogene-activated protein kinases has been suggested (Reimer,
2006). The amino acid glutamine was recently found to stimulate
GLP-1 secretion in control, over weight and diabetic human
volunteers (Greenﬁeld et al., 2009). Glutamine also stimulates GIP
secretion from mouse duodenal cells in primary culture (Parker
et al., 2009). The underlying mechanism has been investigated in
the GLUTag cell line and was at least in part dependent on the
electrogenic uptake of the amino acid, presumably via a system A
transporter (Reimann et al., 2004). Alanine and glycine by contrast
stimulated GLP-1 secretion from the GLUTag cell line due to the
activation of the ionotropic GABA-receptor, a chloride channel,
opening of which resulted in strong depolarization (Gameiro et al.,
2005).
5. Summary and conclusion
GIP-secreting K-cells and GLP-1 secreting L-cells seem to
employ similar molecular sensors to detect the arrival of macro-
nutrients in the gut. Coupling of nutrient transport with the elec-
trogenic uptake of ions provides a direct mechanism to depolarize
the cell plasma membrane, thus enabling non-metabolisable
nutrient analogues to stimulate secretion from these cells. Lipids
seem to act at least partly via activation of speciﬁc G-protein
coupled receptors, which trigger signaling cascades rising cytosolic
Ca2þ and cAMP. Identiﬁcation of the speciﬁc transporters and
receptors involved might allow the manipulation of endogenous
incretin pools in the treatment of obesity and diabetes.
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